Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) have been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $6.25.

Several brokerages have recently weighed in on XERS. Leerink Partners increased their price target on Xeris Biopharma from $5.00 to $6.00 and gave the company an “outperform” rating in a research note on Friday, March 7th. Piper Sandler restated a “neutral” rating and set a $4.00 target price (up previously from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. Jefferies Financial Group restated a “buy” rating and set a $6.00 target price (up previously from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th. Oppenheimer upped their target price on Xeris Biopharma from $6.00 to $7.00 and gave the company an “outperform” rating in a research report on Friday, May 9th. Finally, Craig Hallum upped their target price on Xeris Biopharma from $5.00 to $6.50 and gave the company a “buy” rating in a research report on Friday, March 7th.

Insiders Place Their Bets

In other Xeris Biopharma news, insider Beth Hecht sold 40,000 shares of the stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $5.43, for a total value of $217,200.00. Following the transaction, the insider now owns 1,353,510 shares in the company, valued at approximately $7,349,559.30. This represents a 2.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 6.47% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Legato Capital Management LLC bought a new position in shares of Xeris Biopharma in the fourth quarter valued at approximately $482,000. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Xeris Biopharma by 106.2% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 171,332 shares of the company’s stock valued at $581,000 after purchasing an additional 88,224 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Xeris Biopharma by 1.7% in the fourth quarter. Vanguard Group Inc. now owns 7,899,063 shares of the company’s stock valued at $26,778,000 after purchasing an additional 133,738 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in shares of Xeris Biopharma by 10.5% in the fourth quarter. Principal Financial Group Inc. now owns 113,217 shares of the company’s stock valued at $384,000 after purchasing an additional 10,748 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Xeris Biopharma by 20.8% in the third quarter. JPMorgan Chase & Co. now owns 391,960 shares of the company’s stock valued at $1,117,000 after purchasing an additional 67,557 shares in the last quarter. Institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Trading Up 3.2%

Shares of XERS stock opened at $4.79 on Friday. The stock has a market cap of $749.08 million, a price-to-earnings ratio of -10.64 and a beta of 1.10. The stock has a 50-day moving average of $4.71 and a 200-day moving average of $3.89. Xeris Biopharma has a 1-year low of $1.86 and a 1-year high of $6.07.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.01. The company had revenue of $57.80 million during the quarter, compared to analyst estimates of $57.61 million. Sell-side analysts forecast that Xeris Biopharma will post -0.41 earnings per share for the current year.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.